NCOR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL210194	0.53	7/20
SCHEMBL1067828	0.79	6/20
SCHEMBL1065202	0.74	6/20
SCHEMBL1066870	0.71	6/20
SCHEMBL1064818	0.60	6/20
SCHEMBL210643	0.57	6/20
Mocetinostat (SCHEMBL157027)	1.00	5/20
SCHEMBL209611	0.78	5/20
SCHEMBL253049	0.70	5/20
SCHEMBL210054	0.65	5/20
SCHEMBL1066743	0.60	5/20
SCHEMBL1060973	0.58	5/20
SCHEMBL212876	0.55	5/20
SCHEMBL1063034	1.00	4/20
SCHEMBL213632	0.78	4/20
SCHEMBL211906	0.76	4/20
SCHEMBL209501	0.71	4/20
SCHEMBL212868	0.70	4/20
SCHEMBL213009	0.70	4/20
SCHEMBL210991	0.69	4/20

Clinical trials — most relevant to NCOR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Chronic Effects of Estrogen in Microcirculation	PHASE4	COMPLETED
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?	PHASE4	UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.	PHASE3	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Preoperative Bexarotene Treatment for Cushing's Disease	PHASE1/PHASE2	UNKNOWN
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies	PHASE2	COMPLETED
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer	PHASE2	RECRUITING
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer	nan	UNKNOWN
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Precision High-Intensity Training Through Epigenetics (PHITE)	nan	COMPLETED
Study of Prostate Cancer in Black and White U.S. Veterans	nan	COMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NCOR1 binder may also engage these)

Protein	Name	Similarity
Q4KKX4	—	1.000	Q4KKX4 →
Q60974	—	0.998	Q60974 →
NCOR2	Nuclear receptor corepressor 2	0.995	landscape →
Q8QG78	—	0.993	Q8QG78 →
Q9WU42	—	0.989	Q9WU42 →
Q4LE39	—	0.986	Q4LE39 →
Q5XJV7	—	0.985	Q5XJV7 →
P15336	—	0.985	P15336 →
Q9P2N5	—	0.984	Q9P2N5 →
Q80TJ7	—	0.984	Q80TJ7 →
P16951	—	0.983	P16951 →
Q00969	—	0.983	Q00969 →
Q4VCS5	—	0.983	Q4VCS5 →
P49140	—	0.981	P49140 →
Q9EQM6	—	0.981	Q9EQM6 →
Q9C0A6	—	0.981	Q9C0A6 →
Q62925	—	0.981	Q62925 →
Q3UQU0	—	0.981	Q3UQU0 →
Q9JKL8	—	0.980	Q9JKL8 →
Q9JKB5	—	0.980	Q9JKB5 →
A0A1L8GR68	—	0.980	A0A1L8GR68 →
Q6NXK2	—	0.980	Q6NXK2 →
Q96N64	—	0.980	Q96N64 →
Q5SFM8	—	0.980	Q5SFM8 →
Q62136	—	0.980	Q62136 →
Q5VWG9	—	0.980	Q5VWG9 →
O88974	—	0.979	O88974 →
MAP3K1	Mitogen-activated protein kinase kinase kinase 1	0.979	landscape →
Q9TUG2	—	0.979	Q9TUG2 →
Q8K2W6	—	0.979	Q8K2W6 →